Revised Korean Antiviral Guideline Reduces the Hepatitis B-related Hepatocellular Carcinoma Risk in Cirrhotic Patients

BACKGROUND: Since September 2015, the initiation of antiviral therapy (AVT) for patients with chronic hepatitis B (CHB)-related cirrhosis has been reimbursed according to the revised Korean Association for the Study of Liver (KASL) guideline, if the patient had hepatitis B virus DNA level ≥ 2,000 IU...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, David Sooik, Park, Soo Young, Kim, Beom Kyung, Park, Jun Yong, Kim, Do Young, Han, Kwang-Hyub, Lee, Yu Rim, Tak, Won Young, Kweon, Young Oh, Jung, Inkyung, Han, Minkyung, Kim, Eun Hwa, Ahn, Sang Hoon, Kim, Seung Up
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Academy of Medical Sciences 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8076846/
https://www.ncbi.nlm.nih.gov/pubmed/33904261
http://dx.doi.org/10.3346/jkms.2021.36.e105

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8076846/
https://www.ncbi.nlm.nih.gov/pubmed/33904261
http://dx.doi.org/10.3346/jkms.2021.36.e105

Ejemplares similares